Thorne announced this week that a month-long consumer study of its Creatine + Alpha-GPC powder found more than 60% of the 105 participants improved across multiple areas of cognitive performance on an objective test. Most people noticed a difference fast, with 71% improving across focus, clarity, performance and mood within an average of two days, and 79% noticing a benefit in one of those areas within the first week. The gains held up over the full month, with the strongest results being a 96% average increase in improved motivation and 89% reporting improved focus after four weeks. Ninety percent said they'd recommend the product to friends or family, and 89% wanted to keep using it.
Participants in Thorne's 30-day study noticed a difference in focus, clarity or mood within an average of two days.
The study tested the finished formula rather than the creatine or the Alpha-GPC on their own. It was open-label, without a named research partner or a public trial registration. It's also just one of many. Thorne has completed five clinical and consumer studies this year and has sixteen more underway, with over thirty planned for 2027. That research push is running alongside Procter & Gamble's $3.8bn acquisition of the company.
We're also seeing brands like The Better Menopause making the same bet, but with a different design. The UK brand is putting £100,000 into a placebo-controlled trial of its Better Metabolism product with the University of Southampton, enrolling 80 to 90 women in menopause over 12 weeks. Ritual took a third path when it launched its perimenopause supplement this month, building it around a shatavari extract dosed to match the published research rather than running a trial of its own.
Our read
There's real value in what Thorne is doing here. A study like this moves fast and costs a fraction of a clinical trial, and it tells the company whether people actually notice a difference when they use the product the way it's meant to be used day to day. That's useful information for both internal decisions and marketing to consumers. Where it becomes powerful rather than just useful is when it sits alongside a fully powered, placebo-controlled trial like the one The Better Menopause is running with Southampton. The consumer study tells you people feel a difference. The gold-standard trial tells you that difference is real rather than placebo or expectation. Brands that pair the two get the fast signal and the proof that holds up, rather than having to choose between them.
Sources: Thorne press release, NI The Better Menopause's Southampton trial, NI on Ritual's perimenopause launch, NO on the P&G-Thorne acquisition


